Lexpos News

In light of surveillance data indicating that circulation of influenza in the community has returned to baseline levels, the Department of Health and Social Care has published an alert to inform prescribers working in primary care and pharmacy teams that antiviral medicines should no longer be prescribed.  Community pharmacists should no longer supply antiviral medicines [...]

The post End of antiviral medicine prescribing for 2024/25 influenza season appeared first on Community Pharmacy England.

Following representations made by Community Pharmacy England on behalf of community pharmacy owners, the Department of Health and Social Care (DHSC) has retrospectively adjusted the reimbursement prices of certain products dispensed in March 2025. Under the current price change mechanism, pharmacy owners would have to wait one (or in some cases two months) before any NHS list prices changes are applied to reimbursement of branded products. The delays in reimbursement prices catching [...]

The post Retrospective reimbursement price adjustments for March 2025 appeared first on Community Pharmacy England.

Pharmacy teams can help to raise awareness by displaying posters in their pharmacy to remind patients about the savings they can make with prepayment certificates (PPCs). PPCs offer savings for those needing multiple prescription items or when a patient is prescribed a listed HRT medicine. The cost of each type of PPC has been frozen for [...]

The post Promoting NHS prescription prepayment certificates appeared first on Community Pharmacy England.

On Monday 31st March 2025, the details of the contractual settlement for 2025/26 were announced, which included a continuation of the Pharmacy First service, including clinical pathways consultations. As part of this continuation, the capping methodology put in place during the second half of 2024/25 was also carried over into the 2025/26 arrangements. This means that [...]

The post Pharmacy First cap FAQs appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Various Chemidex Pharma Ltd Products Drug alert number: EL(25)A/21 Date issued: 13 May 2025 Chemidex Pharma Ltd has informed the MHRA that the Patient Information Leaflet (PIL) in their topical steroid products does not contain all the required safety information. Cartons for the products/batches listed are missing side effect information [...]

The post MHRA Class 4 Medicines Defect Notification: Various Chemidex Pharma Ltd Products appeared first on Community Pharmacy England.